A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
Public ClinicalTrials.gov record NCT06410924. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Treatment With DD01 for 48 Weeks in Overweight/Obese Subjects With MASLD/MASH
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
Study identification
- NCT ID
- NCT06410924
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 67 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 13, 2024 (Actual)
- Primary completion
- May 20, 2025 (Actual)
- Completion
- Apr 21, 2026 (Actual)
- Last update posted
- May 1, 2026
2024 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 4
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Summit Research Site | Maitland | Florida | 92751 | — |
| Summit Research Site | Monroe | Louisiana | 71201 | — |
| Summit Research Site | West Monroe | Louisiana | 71291 | — |
| Summit Research Site | Kansas City | Missouri | 64131 | — |
| Summit Research Site | Austin | Texas | 78757 | — |
| Summit Research Site | Bellaire | Texas | 77401 | — |
| Summit Research Site | Brownsville | Texas | 78520 | — |
| Summit Research Site | Corpus Christi | Texas | 78404 | — |
| Summit Research Site | Edinburg | Texas | 78539 | — |
| Summit Research Site | Georgetown | Texas | 78626 | — |
| Summit Research Site | San Antonio | Texas | 78222 | — |
| Summit Research Site | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06410924, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06410924 live on ClinicalTrials.gov.